NCT01577472View on ClinicalTrials.gov

Efficacy Study Comparing the Effect of Clomiphencitrate to an Antagonist Protocol

PHASE4CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

November 14, 2017

Study Completion Date

November 14, 2017

Conditions
Female InfertilityOvarian Insufficiency
Interventions
DRUG

High Dose Clomiphencitrat

100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).

DRUG

Low Dose Clomiphencitrat

100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).

DRUG

High Dose Placebo

Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).

DRUG

Low dose Placebo

Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).

Trial Locations (1)

4031

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT01577472 - Efficacy Study Comparing the Effect of Clomiphencitrate to an Antagonist Protocol | Biotech Hunter | Biotech Hunter